DHA / EPA compound capsule for dyslipidemia and digital asthenopia and application of DHA / EPA compound capsule

Abstract

The invention relates to DHA / EPA (docosahexaenoic acid / eicosapentaenoic acid) compound capsules for dyslipidemia and digital asthenopia and application of the DHA / EPA compound capsules. The DHA / EPA compound capsules are prepared from high-purity ocean-derived Omega-3 fatty acid ethyl ester, coenzyme Q10 and The capsule is prepared by adopting a low-temperature emulsification-double-layer embedding process: firstly, carrying out pre-emulsification to form a stable micro-emulsion, then forming double-layer protective particles through complex coacervation embedding and enteric coating, and finally pressing into the capsule. Through the synergistic effect of the components, the composition has multiple prevention effects in the aspects of regulating blood fat, resisting inflammation, resisting oxidation and improving the vascular endothelial function, the process ensures the long-term stability and synergistic bioavailability of the active components, and an innovative nutrition intervention scheme is provided for first-level prevention of cardiovascular and cerebrovascular diseases.

Description

Technical Field

[0001] This invention relates to the field of health product technology, specifically to a DHA / EPA compound capsule for treating dyslipidemia and digital vision fatigue, and its application. Background Technology

[0002] With changes in lifestyle, dyslipidemia has become a prevalent health problem worldwide, increasing the risk of cardiovascular disease. Meanwhile, digital eye strain caused by prolonged use of electronic devices has become a common health concern, manifesting as symptoms such as dry eyes, eye irritation, and blurred vision, and in severe cases, it can even affect retinal health.

[0003] In existing technologies, most health supplements for regulating blood lipids use EPA / DHA fish oil as the core ingredient, primarily regulating blood lipids through EPA and improving vascular endothelial function through DHA, but lacking targeted protection for eye health. Meanwhile, products for relieving eye fatigue mainly focus on eye nutrients such as lutein and zeaxanthin, failing to address the need for blood lipid regulation. Furthermore, existing compound products have the following shortcomings:

[0004] 1. An unbalanced ratio of DHA to EPA makes it difficult to simultaneously meet the dual needs of blood lipid regulation and eye nutrition.

[0005] 2. The lack of scientifically formulated synergistic components means that there is no synergistic effect between eye nutrients and lipid-regulating components;

[0006] 3. Poor ingredient stability: DHA / EPA is easily oxidized and deteriorates, and ingredients such as lutein are easily degraded, affecting the product's shelf life and efficacy;

[0007] 4. Insufficient bioavailability and unreasonable formulation and preparation process lead to incomplete absorption of active ingredients and failure to fully exert their effects.

[0008] Based on this, the present invention proposes a DHA / EPA compound capsule and its application for treating dyslipidemia and digital vision fatigue. By optimizing the DHA / EPA ratio, scientifically compounding synergistic components, and improving the preparation process, it achieves the dual effects of regulating blood lipids and protecting the eyes, thus solving the technical defects of existing products. Summary of the Invention

[0009] To achieve the above objectives, the present invention provides the following technical solution:

[0010] A DHA / EPA compound capsule targeting dyslipidemia and digital vision strain

[0011] This compound capsule consists of contents and a capsule shell, in parts by weight:

[0012] 1. Contents composition

[0013] Key ingredients: 30-50 parts DHA-enriched fish oil (DHA content 25-35%), 20-40 parts EPA-enriched fish oil (EPA content 20-30%). The ratio of DHA to EPA is controlled between 1.2:1 and 2.5:1, which can both lower triglycerides and inhibit platelet aggregation through EPA, and nourish the retina and improve nerve function through DHA, thus meeting the dual needs of efficacy.

[0014] Synergistic ingredients: 0.5-2 parts lutein, 0.1-0.5 parts zeaxanthin (mixed in a 5:1-4:1 ratio to precisely target the macular region of the retina and filter blue light damage); 1-3 parts B vitamins (a mixture of vitamins B1, B6, and B12 in a 1:2:1 ratio to improve nerve metabolism and relieve eye fatigue); 0.05-0.2 parts zinc (derived from zinc gluconate or zinc citrate to promote retinal enzyme activity).

[0015] Co-ingredients: Vitamin E 0.8-2 parts, tea polyphenols 0.3-1 parts (dual antioxidant, inhibiting DHA / EPA oxidation); soybean lecithin 3-8 parts (emulsifier, improving component dispersibility); flaxseed oil 2-6 parts (supplementing α-linolenic acid, converting it into DHA / EPA, enhancing synergistic effects).

[0016] Excipients: 2-5 parts, a mixture of antioxidant (TBHQ), emulsifier (polyglycerol fatty acid ester), and cosolvent (polyethylene glycol 400) in a weight ratio of 2:3:4 to improve stability and solubility.

[0017] 2. Capsule shell components

[0018] Gelatin 40-60 parts, hydroxypropyl methylcellulose 5-10 parts (to improve capsule stability and compatibility), glycerin 15-25 parts, water 20-30 parts, sorbitol 1-4 parts, methylparaben 0.1-0.3 parts (preservative).

[0019] 3. Preferred Solution

[0020] Optimal ingredient ratio: 40 parts DHA-enriched fish oil (30% DHA), 30 parts EPA-enriched fish oil (25% EPA), 1 part lutein, 0.3 parts zeaxanthin, 2 parts B vitamins, 0.1 parts zinc, 1.5 parts vitamin E, 0.6 parts tea polyphenols, 5 parts soy lecithin, 4 parts flaxseed oil, and 3.5 parts excipients.

[0021] The optimal ratio for capsule shells is: 50 parts gelatin, 8 parts hydroxypropyl methylcellulose, 20 parts glycerin, 25 parts water, 2 parts sorbitol, and 0.2 parts methylparaben.

[0022] Preparation process

[0023] The preparation process of this compound capsule includes the following steps:

[0024] 1. Raw material pretreatment: Purify fish oil to remove heavy metals and impurities, crush insoluble components, and prepare antioxidant premix to prevent premature oxidation of components.

[0025] 2. Contents preparation: Vacuum nitrogen protection emulsification is used, and temperature is controlled and stirred in stages to ensure that all components are evenly dispersed and form a stable emulsion.

[0026] 3. Capsule shell preparation: The mixed raw materials are heated and dissolved, and vacuum degassing is performed to ensure the quality of capsule forming.

[0027] 4. Capsule preparation: After rotary pressing, the capsules are dried in stages to precisely control the moisture content and improve their stability.

[0028] 5. Post-processing: The products undergo sorting, light inspection, packaging, and sterilization to ensure they meet quality standards.

[0029] This invention also discloses the application of this compound capsule in the preparation of health products or functional foods that improve dyslipidemia and relieve digital vision fatigue. This compound capsule can regulate lipid metabolism, protect the retina, and relieve eye fatigue, making it suitable for people with dyslipidemia who use electronic devices for extended periods, office workers, and the elderly. It can be formulated into daily health products or functional foods to meet the health needs of specific populations.

[0030] The technical effects and advantages of this invention are as follows:

[0031] 1. Synergistic Effect, Dual Benefits: This invention achieves a synergistic effect of regulating blood lipids and protecting the eyes through the scientific combination of DHA / EPA with lutein, zeaxanthin, and other ingredients. EPA regulates blood lipids and improves vascular endothelium, DHA nourishes the retina, lutein and zeaxanthin filter blue light, and B vitamins and zinc relieve nerve fatigue, overcoming the limitations of single-function products and simultaneously meeting dual health needs.

[0032] 2. Optimized ratios for enhanced targeting: DHA and EPA are blended in a ratio of 1.2:1 to 2.5:1, and lutein and zeaxanthin are blended in a ratio of 5:1 to 4:1. This precisely matches the pathological needs of dyslipidemia and digital vision fatigue, making the efficacy more targeted compared to existing randomly blended products.

[0033] 3. High stability and long shelf life: Through a complex antioxidant system composed of vitamin E, tea polyphenols and TBHQ, combined with nitrogen-protected emulsification and segmented drying processes, the product effectively inhibits the oxidation of DHA / EPA and the degradation of lutein. The product has a shelf life of more than 24 months under the conditions of 25℃ and 60% relative humidity, and the oxidation indicators all meet the national standards.

[0034] 4. High bioavailability: The ratio of soybean lecithin to solubilizer is optimized, and a two-stage emulsification process is adopted to form a uniform oil-in-water emulsion. Human trials have verified that the absorption rate of DHA and EPA is increased by more than 35% compared with traditional fish oil capsules, and the absorption rate of lutein is increased by more than 40%, ensuring full absorption and utilization of effective ingredients.

[0035] High safety and wide applicability: The formula contains no artificial colors or flavors, and all excipients meet food-grade standards. The capsule shell is compounded with plant-based ingredients to reduce gastrointestinal irritation and is suitable for long-term use. The dosage can be adjusted according to the needs of different groups and is suitable for a wide range of people, including those with dyslipidemia and digital vision fatigue, middle-aged and elderly people who want to maintain their health, and office workers. Attached Figure Description

[0036] To facilitate understanding by those skilled in the art, the present invention will be further described below with reference to the accompanying drawings;

[0037] Figure 1 This is a flow chart illustrating the preparation process of the compound capsules of the present invention. Detailed Implementation

[0038] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention.

[0039] Example 1

[0040] A DHA / EPA compound capsule for treating dyslipidemia and digital vision fatigue, the contents of which by weight are: 30 parts DHA-enriched fish oil (DHA 25%), 20 parts EPA-enriched fish oil (EPA 20%), 0.5 parts lutein, 0.1 parts zeaxanthin, 1 part B vitamins, 0.05 parts zinc, 0.8 parts vitamin E, 0.3 parts tea polyphenols, 3 parts soybean lecithin, 2 parts flaxseed oil, and 2 parts excipients (antioxidant: emulsifier: solubilizer = 2:3:4).

[0041] The capsule shell, by weight, contains: 40 parts gelatin, 5 parts hydroxypropyl methylcellulose, 15 parts glycerin, 20 parts water, 1 part sorbitol, and 0.1 parts methylparaben.

[0042] The preparation process is as follows:

[0043] 1. Raw material pretreatment: Fish oil is purified by molecular distillation, lutein and zeaxanthin are pulverized to 120 mesh, and vitamin E, tea polyphenols and TBHQ are mixed to prepare a premix;

[0044] 2. Preparation of contents: Mix fish oil and flaxseed oil, stir at 45℃ and 300 r / min for 15 minutes, add the remaining ingredients, emulsify and stir at 60℃ and 600 r / min for 30 minutes, cool to 35℃ and stir for 10 minutes, filter and set aside;

[0045] 3. Capsule shell preparation: Mix capsule shell raw materials in proportion, heat to 70℃ to dissolve, keep warm and stir for 30 minutes, add methylparaben, and vacuum degas for 20 minutes;

[0046] 4. Capsule preparation: Press to a specification of 0.8 g / capsule, dry at 25℃ and 40% humidity for 4 hours, and then dry at 30℃ and 30% humidity for 8 hours;

[0047] 5. Post-processing: sorting, light inspection, packaging, sterilization to obtain the finished product.

[0048] Example 2

[0049] A DHA / EPA compound capsule for treating dyslipidemia and digital vision fatigue, the contents of which by weight are: 40 parts DHA-enriched fish oil (30% DHA), 30 parts EPA-enriched fish oil (25% EPA), 1 part lutein, 0.3 parts zeaxanthin, 2 parts B vitamins, 0.1 parts zinc, 1.5 parts vitamin E, 0.6 parts tea polyphenols, 5 parts soybean lecithin, 4 parts flaxseed oil, and 3.5 parts excipients (antioxidant: emulsifier: solubilizer = 2:3:4).

[0050] The capsule shell, by weight, contains: 50 parts gelatin, 8 parts hydroxypropyl methylcellulose, 20 parts glycerin, 25 parts water, 2 parts sorbitol, and 0.2 parts methylparaben.

[0051] The preparation process is as follows:

[0052] 1. Raw material pretreatment: Fish oil is purified by molecular distillation, lutein and zeaxanthin are pulverized to 130 mesh, and vitamin E, tea polyphenols and TBHQ are mixed to make a premix;

[0053] 2. Preparation of contents: Mix fish oil and flaxseed oil, stir at 50℃ and 400 r / min for 18 minutes, add the remaining ingredients, emulsify and stir at 62℃ and 700 r / min for 35 minutes, cool to 38℃ and stir for 12 minutes, filter and set aside;

[0054] 3. Capsule shell preparation: Mix capsule shell raw materials in proportion, heat to 75℃ to dissolve, keep warm and stir for 35 minutes, add methylparaben, and vacuum degas for 25 minutes;

[0055] 4. Capsule preparation: Press to a specification of 1.0 g / capsule, dry at 28℃ and 45% humidity for 5 hours, and then dry at 32℃ and 35% humidity for 10 hours;

[0056] 5. Post-processing: sorting, light inspection, packaging, sterilization to obtain the finished product.

[0057] Example 3

[0058] A DHA / EPA compound capsule for treating dyslipidemia and digital vision fatigue, the contents of which by weight are: 50 parts DHA-enriched fish oil (35% DHA), 40 parts EPA-enriched fish oil (30% EPA), 2 parts lutein, 0.5 parts zeaxanthin, 3 parts B vitamins, 0.2 parts zinc, 2 parts vitamin E, 1 part tea polyphenols, 8 parts soybean lecithin, 6 parts flaxseed oil, and 5 parts excipients (antioxidant: emulsifier: solubilizer = 2:3:4).

[0059] The capsule shell, by weight, contains: 60 parts gelatin, 10 parts hydroxypropyl methylcellulose, 25 parts glycerin, 30 parts water, 4 parts sorbitol, and 0.3 parts methylparaben.

[0060] The preparation process is as follows:

[0061] 1. Raw material pretreatment: Fish oil is purified by molecular distillation, lutein and zeaxanthin are pulverized to 150 mesh, and vitamin E, tea polyphenols and TBHQ are mixed to make a premix;

[0062] 2. Preparation of contents: Mix fish oil and flaxseed oil, stir at 55℃ and 500 r / min for 20 minutes, add the remaining ingredients, emulsify and stir at 65℃ and 800 r / min for 40 minutes, cool to 40℃ and stir for 15 minutes, filter and set aside;

[0063] 3. Capsule shell preparation: Mix capsule shell raw materials in proportion, heat to 80℃ to dissolve, keep warm and stir for 40 minutes, add methylparaben, and vacuum degas for 30 minutes;

[0064] 4. Capsule preparation: Press to a specification of 1.2 g / capsule, dry at 30℃ and 50% humidity for 6 hours, and then dry at 35℃ and 40% humidity for 12 hours;

[0065] 5. Post-processing: sorting, light inspection, packaging, sterilization to obtain the finished product.

[0066] Performance testing

[0067] The performance of the compound capsules prepared in Example 2 was tested, and the results are as follows:

[0068] 1. Ingredient content: DHA 12.1%, EPA 7.4%, lutein 0.29%, zeaxanthin 0.09%, and the content of other ingredients meets the requirements of the formula design;

[0069] 2. Stability: After 24 months of storage at 25℃ and 60% relative humidity, the peroxide value is 4.7 mmol / kg, the acid value is 0.7 mg KOH / g, the lutein retention rate is 85%, and there is no off-odor or separation.

[0070] 3. Bioavailability: Human trials show that the absorption rates of DHA (83.2%), EPA (81.5%), and lutein (78.6%) are 36.8%, 34.2%, and 41.3% higher than traditional single-function products, respectively.

[0071] 4. Efficacy Verification: One hundred volunteers with dyslipidemia and digital vision fatigue were selected. They took one capsule daily for three consecutive months. Serum triglycerides decreased by an average of 23.5%, and total cholesterol decreased by 18.2%. The improvement rate of eye fatigue symptoms (dry eyes, eye strain, blurred vision) reached 89%.

[0072] 5. Safety: Acute toxicity tests showed LD50 > 10 g / kg. After 6 months of long-term use, no abnormalities were observed in liver and kidney function or blood routine indicators in the subjects, and no adverse reactions were reported.

[0073] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any variations or substitutions that can be easily conceived by those skilled in the art within the technical scope disclosed in the present invention should be included within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.

Claims

1. A DHA / EPA compound capsule for treating dyslipidemia and digital vision fatigue, characterized in that, Composed of contents and capsule shell, by weight: The contents include: 30-50 parts DHA-enriched fish oil (DHA content 25-35%), 20-40 parts EPA-enriched fish oil (EPA content 20-30%), 0.5-2 parts lutein, 0.1-0.5 parts zeaxanthin, 1-3 parts B vitamins, 0.05-0.2 parts zinc, 0.8-2 parts vitamin E, 0.3-1 part tea polyphenols, 3-8 parts soybean lecithin, 2-6 parts flaxseed oil, and 2-5 parts excipients; The excipients are composed of antioxidants, emulsifiers and cosolvents in a weight ratio of 2:3:4, wherein the antioxidant is tert-butylhydroquinone (TBHQ), the emulsifier is polyglycerol fatty acid ester, and the cosolvent is polyethylene glycol 400. The capsule shell consists of: 40-60 parts gelatin, 5-10 parts hydroxypropyl methylcellulose, 15-25 parts glycerin, 20-30 parts water, 1-4 parts sorbitol, and 0.1-0.3 parts methylparaben.

2. The DHA / EPA compound capsules for treating dyslipidemia and digital vision fatigue according to claim 1, characterized in that, The B vitamins include vitamin B1, vitamin B6, and vitamin B12, mixed in a weight ratio of 1:2:1; the zinc element is derived from zinc gluconate or zinc citrate.

3. The DHA / EPA compound capsules for treating dyslipidemia and digital vision fatigue according to claim 1, characterized in that, The optimal weight ratio of the contents is as follows: 40 parts DHA-enriched fish oil (30% DHA content), 30 parts EPA-enriched fish oil (25% EPA content), 1 part lutein, 0.3 parts zeaxanthin, 2 parts B vitamins, 0.1 parts zinc, 1.5 parts vitamin E, 0.6 parts tea polyphenols, 5 parts soybean lecithin, 4 parts flaxseed oil, and 3.5 parts excipients.

4. The DHA / EPA compound capsules for treating dyslipidemia and digital vision fatigue according to claim 1, characterized in that, The optimal weight ratio of the capsule shell is: 50 parts gelatin, 8 parts hydroxypropyl methylcellulose, 20 parts glycerin, 25 parts water, 2 parts sorbitol, and 0.2 parts methylparaben.

5. A preparation process for DHA / EPA compound capsules targeting dyslipidemia and digital vision fatigue, characterized in that, Includes the following steps: S1. Raw material pretreatment: DHA-enriched fish oil and EPA-enriched fish oil are purified by molecular distillation, with acid value controlled at ≤1.0 mgKOH / g and peroxide value at ≤5.0 mmol / kg; lutein and zeaxanthin are pulverized to 120-150 mesh; vitamin E, tea polyphenols and antioxidants are mixed to prepare a premix. S2. Contents preparation: Take DHA-enriched fish oil, EPA-enriched fish oil and flaxseed oil according to the formula and put them into a vacuum emulsification tank. Pour nitrogen gas for protection and stir at 45-55℃ and 300-500 r / min for 15-20 minutes. Add soybean lecithin, lutein, zeaxanthin, B vitamins, zinc, and premix in sequence. Heat to 60-65℃ and emulsify and stir at 600-800 r / min for 30-40 minutes. Add the remaining excipients, cool to 35-40℃, and stir at 150-200 r / min for 10-15 minutes. Filter through a 200-mesh sieve for later use. S3. Capsule shell preparation: Mix gelatin, hydroxypropyl methylcellulose, glycerin, sorbitol and water according to the formula, heat to 70-80℃ to dissolve, keep warm and stir for 30-40 minutes; add methylparaben, degas under vacuum of 0.06-0.08 MPa for 20-30 minutes; S4. Capsule preparation: The capsules are pressed using a rotary soft capsule machine to a size of 0.8-1.2 g / capsule; they are first dried at 25-30℃ and 40-50% relative humidity for 4-6 hours, and then dried at 30-35℃ and 30-40% relative humidity for 8-12 hours, controlling the moisture content of the capsules to 8-12%. S5. Post-processing: Selection and impurity removal, light inspection, aluminum-plastic packaging, and sterilization with 60Co-γ rays (dose 5-8 kGy) to obtain the finished product.

6. The preparation process of DHA / EPA compound capsules for treating dyslipidemia and digital vision fatigue according to claim 5, characterized in that, In step S2, the optimal parameters for emulsification and stirring are: temperature 62℃, stirring speed 700 r / min, and stirring time 35 minutes.

7. The preparation process of DHA / EPA compound capsules for treating dyslipidemia and digital vision fatigue according to claim 5, characterized in that, In step S4, the optimal drying parameters are: first stage temperature 28℃, relative humidity 45%, drying time 5 hours; second stage temperature 32℃, relative humidity 35%, drying time 10 hours.

8. The application of the DHA / EPA compound capsules for treating dyslipidemia and digital vision fatigue as described in any one of claims 1-4 in the preparation of health products or functional foods that improve dyslipidemia and relieve digital vision fatigue.

Images